For the risk stratification of indeterminate thyroid nodules
For the risk stratification of indeterminate thyroid nodules
Please visit us at ENDOExpo 2024 (Booth 626)
The addition of genetic analysis to the evaluation of thyroid FNA samples improves diagnostic accuracy of indeterminate thyroid nodules. This study evaluated the ability of interdependent pairwise microRNA expression analysis ...
This study demonstrated the analytical and clinical validity of a pairwise microRNA (miRNA) analysis for the detection of medullary thyroid cancer (MTC) using ThyraMIR® Thyroid miRNA Classifier. miRNA classification was ...
Multicenter, retrospective, blinded validation study of 309 subjects with indeterminate thyroid nodules (Bethesda III, IV, or V) and corresponding surgical histology. Gold-standard unanimous consensus histopathology diagnosis (n=197) among three pathologists ...
This paper discusses the development of an expanded mutation panel (ThyGeNEXT®). Additionally, it demonstrates the analytical validation of the expanded NGS panel test and compares analytical characteristics of ThyGeNEXT to the ...
This multicenter prospective observational study evaluated the use of a mutation detection and miRNA expression algorithm to improve the diagnostic yield of molecular testing for thyroid nodules. 109 thyroid nodules ...
This large, blinded, observational study was conducted by the Allegheny Health Network. There were 338 samples with either an Atypia of Undetermined Significance (Bethesda III) or a Follicular Neoplasm (Bethesda ...
A systematic review of the literature was conducted in addition to an analysis of molecular data generated from fine needle aspiration biopsies (FNAB). Twenty-one studies from 12 countries involving 2036 preoperative ...
This study evaluated the clinical performance of ThyGeNEXT®, an expanded mutation panel of strong and weak drivers of oncogenic changes, used in combination with ThyraMIR®, a microRNA classifier for the ...
In this study, molecular results from 12,993 consecutive patient samples were reviewed for cases that either underwent testing with a focused mutation panel (n=8619) or an expanded mutation panel (ThyGeNEXT®, ...
This multicenter, observational, real-world clinical experience study examined the likelihood of patients with indeterminate thyroid nodules to undergo surgery or have malignant outcomes based on multiplatform combination mutation and microRNA ...
In this study, real-world clinical results of molecular testing for indeterminate thyroid nodules were analyzed based upon Bethesda categorization, mutation analysis, and microRNA classifier results and were correlated to show ...
The purpose of this study was to determine the health outcome benefits and cost-effectiveness of molecular testing in nodules with AUS/FLUS or FN/SFN cytology. The initial diagnosis and treatment of ...
This study was designed to determine if routinely prepared thyroid FNA cytology smears can be used for molecular profiling by NGS for oncogene mutations and oncogenic fusion transcripts, and by ...
This study examined a comprehensive evaluation of miRNA gene expression in diverse thyroid lesions (n=534) and developed predictive models for the classification of thyroid nodules. miRNA-based classifiers complemented and significantly ...
This meta-analysis analyzed the impact of molecular testing on surgical decision-making in indeterminate thyroid nodules. This meta-analysis included data from 31 studies, including 4,464 indeterminate thyroid nodules, and evaluated the ...
Molecular alteration patterns were demonstrated to provide an accurate prediction of tumor behavior in papillary thyroid carcinoma (PTC) compared to tumor size alone. The study involved 718 patients who underwent ...
This study evaluated the concordance of surgical outcomes with the molecular test results from ThyGeNEXT + ThyraMIR/ThyraMIRv2 testing and the false negative rate in a cohort of cases with a ...
The following independent studies encompass in vitro, in vivo, and clinical research designed to explore the biological functions of microRNAs. They underscore the role of microRNAs as master regulators of gene expression and their relevance to thyroid cancer biology and processes. Although some of these studies include microRNAs assessed by the ThyraMIR®v2 assay, they should not be interpreted as validation studies for ThyraMIRv2 or the ThyGeNEXT® + ThyraMIRv2 combination testing platform.
This study analyzed miR-222 expression, one of the most consistently overexpressed microRNAs found in papillary thyroid carcinoma (PTC), and its correlation with American Thyroid Association® (ATA) risk stratifications. Researchers analyzed ...
microRNAs (miRNAs) regulate gene expression and are critical in cancer initiation and progression. This study examined the in vitro and in vivo effects of miR-29b-3p in papillary thyroid carcinoma (PTC). ...
This study identified miR-146b as the most overexpressed microRNA in papillary thyroid carcinoma (PTC), directly targeting DICER1, an RNAse III-type enzyme involved in microRNA processing. By targeting DICER1, miR-146b inhibits ...
This is an industry sponsored webinar. Publication and promotion of this webinar do not imply endorsement of the test, its clinical utility, or the broader topic by the Journal Thyroid, its editorial leadership, the publisher, or the American Thyroid Association.
) within the control bar to navigate this video's chapters Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.
